scholarly journals Disorders of sexual function in postmenopausal patients

2021 ◽  
pp. 106-111
Author(s):  
A. Z. Khashukoeva ◽  
M. V. Burdenko ◽  
A. V. Overko ◽  
T. E. Ryzhova ◽  
M. S. Safonina
Keyword(s):  
Sexual Dysfunction ◽  
Sexual Function ◽  
Postmenopausal Women ◽  
Sexual Desire ◽  
Hormone Replacement ◽  
Treatment Options ◽  
Non Invasive ◽  
Physiological Processes ◽  
Sexual Pain ◽  
Post Menopausal

Introduction. Research in recent years has shown that sexual dysfunction is now common in post-menopausal women and that it has a significant impact on their quality of life.Aim: to identify the major causes of sexual dysfunction in postmenopausal women and their treatment options, by analysing different literature sources.Materials and methods. During the study of this problem, 25 sources of literature, both Russian and foreign, dating from 2007 to 2020 were analysed.Results and discussion. The main etiological aspects of sexual dysfunction in postmenopausal women, such as disorders of sexual desire, sexual pain disorders, orgasmic disorders are considered in this article. The role of physiological processes occurring in a woman’s organism during this age period in the formation of sexual dysfunction is presented, namely, the influence of insufficiency of sex hormones (In particular, estrogens) and genitourinary syndrome on disorders of the sexual sphere.The main methods of treatment are described, including hormone replacement therapy, the use of non-invasive laser technology, and surgical correction of the dysfunction and atrophy of the pelvic floor muscles. Particular attention is paid to the use of the synthetic steroid tibolone and flibanserin, a drug used to treat hypoactive sexual desire disorder, and the data concerning their high efficacy are presented.Conclusions. The predominant manifestation of sexual dysfunction are disorders of sexual desire and sexual pain disorders. Thus it is important to pay attention to this problem and to treat sexual dysfunction by treating its causes.Conclusion. The treatment of sexual dysfunction must address the causes. In many cases, psychotherapy is necessary. MHT has a positive effect on the sexual function of patients. Testosterone therapy is justified in this case, but is rarely used, as it has a number of side effects and contraindications. Synthetic steroids (Tibolone) have shown good results in the treatment of sexual dysfunction.

scholarly journals O Papel da Testosterona na Melhoria do Desejo Sexual da Mulher Pós-Menopáusica: Uma Revisão Baseada na Evidência

2018 ◽  
Vol 31 (11) ◽  
pp. 680
Author(s):  
Maria Gouveia ◽  
Raquel Sanches ◽  
Sara Andrade ◽  
Sara Carmona ◽  
Carolina Ferreira
Keyword(s):  
Sexual Dysfunction ◽  
Sexual Function ◽  
Randomized Controlled Trials ◽  
Postmenopausal Women ◽  
Sexual Desire ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled

Introduction: Female sexual dysfunction is a common problem, affecting more than 1/3 of women during their lives. The aim of this review is to review the evidence for the effectiveness of testosterone in sexual dysfunction in postmenopausal women, particularly in the improvement of sexual desire.Material and Methods: The authors searched in international databases National Guidelines Clearinghouse, Guidelines Finder, Cochrane Library and MEDLINE/PubMed, for guidelines, systematic reviews, meta-analysis and randomized controlled trials, published between January 2005 and February 2017, using the MeSH terms ‘testosterone’, ‘androgens’, ‘libido’, ‘sexual dysfunctions’ and ‘menopause’.Results: From a pool of 506 articles, 11 were selected: three guidelines, one systematic review with meta-analysis and seven randomized controlled trials. The selected articles showed testosterone‘s efficacy on global sexual function and improvement of sexual desire in postmenopausal women, when both are used in monotherapy or in association with other hormones. No study showed changes in hepatic enzymes or serious adverse effects.Discussion: The small sample size and short follow-up used in the included studies limits the ability to assess testosterone’s long-term benefits and effects.Conclusion: At short-term, testosterone seems to improve sexual function in postmenopausal women, particularly sexual desire. Nevertheless, more studies with larger sample size and longer follow-up are needed to understand its long-term safety and effectiveness.

The Relationship between Personality Types and Sexual Dysfunction

2020 ◽  
Vol 17 ◽  
Author(s):  
Fatemeh Hosseini ◽  
Zahra Beygi ◽  
Zahra Yazdanpanahi ◽  
Marzieh Akbarzadeh
Keyword(s):  
Sexual Dysfunction ◽  
Sexual Function ◽  
Sexual Desire ◽  
Study Data ◽  
Personality Types ◽  
Chi Square ◽  
Cross Sectional ◽  
Exact Test ◽  
Sexual Pain ◽  
Arousal Disorder

Background: Sexual function is affected by various physiological and psychological factors. Individual differences and various personality types are effective in response to sexual function. Objective: The present study aimed to investigate the correlation between sexual function and personality types among the women referred to healthcare centers in Shiraz in 2014-2015. Methods: This cross-sectional, descriptive-analytical study was conducted on 514 women referred to healthcare centers in Shiraz. The study data were collected using a demographic information form, Female Sexual Function Index, and NEO Personality Inventory. Written informed consent forms were also obtained from the participants. After all, the data were analysed through the SPSS software, version 19, using t-test, chi-square test, and Fisher’s exact test. Results: The results showed that sexual desire disorder in 39% of the participants, sexual arousal disorder in 38.6%, orgasm disorder in 25.5%, and sexual pain in 33%. The results also indicated that sexual desire, arousal, and pain were significantly associated with extroversion and reversely related to neuroticism. Conclusions: The score of extroversion was higher in the individuals without sexual dysfunction, while the score of neuroticism was higher among those with sexual dysfunction. Therefore, it is necessary to evaluate the women’s personality types as a technique for assessment of sexual dysfunction.

scholarly journals The Impact of Metabolic Syndrome and Its Components on Female Sexual Dysfunction: A Narrative Mini-Review

2018 ◽  
Vol 12 (2) ◽  
pp. 57-63
Author(s):  
Simona Di Francesco ◽  
Marika Caruso ◽  
Iole Robuffo ◽  
Andrea Militello ◽  
Elena Toniato
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Sexual Dysfunction ◽  
Arterial Hypertension ◽  
Sexual Function ◽  
Sexual Desire ◽  
Female Sexual Dysfunction ◽  
Systemic Arterial Hypertension ◽  
The Metabolic Syndrome ◽  
The Impact

Background: The impact of metabolic syndrome on female sexual dysfunction received modest consideration in clinical practice. The aim of the research was to analyze the international literature to determine the relationship between the metabolic syndrome, its components and female sexual disorders. Methods: We identified relevant full-length papers by electronic databases as Index Medicus/Medline, Scopus, Life Science Journals, from 2005 to the present. Studies were searched using the following as search query: metabolic syndrome, female sexual dysfunction, obesity, systemic arterial hypertension, diabetes mellitus, dyslipidemia. Results: Women with metabolic syndrome showed higher prevalence of sexual inactivity and low sexual desire, orgasm and satisfaction respect to women without metabolic syndrome. Particularly metabolic components as diabetes mellitus, dy-slipidemia, systemic arterial hypertension were strongly associated with lower sexual desire, activity and Female Sexual Function Index total score. In contrast, other studies showed no relationship. Conclusion: Our study showed that in the clinical evaluation of women with metabolic syndrome routine inquiring about female sexual dysfunction should be recommended to ameliorate sexual function and quality of life. However more prospective and longitudinal studies on the sexual effects of metabolic syndrome should also be suggested to know the factors related to women's sexuality better.

scholarly journals High dietary daidzein intake lowers cholesterol levels among post-menopausal women

2020 ◽  
Vol 39 (1) ◽  
pp. 47
Author(s):  
Elly Herwana ◽  
Pusparini Pusparini ◽  
Audria Graciela
Keyword(s):  
Postmenopausal Women ◽  
Ldl Cholesterol ◽  
Hormone Replacement ◽  
Colorimetric Method ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Lowering Effect ◽  
Cholesterol Levels ◽  
Menopausal Women ◽  
Post Menopausal

Background<br />Menopause is associated with changes in metabolic profile. Although hormone replacement therapy (HRT) has been shown to have beneficial effects on lipid metabolism, its adverse effects have indicated a need for alternative estrogen-based treatments. Several investigations have evaluated the effects of isoflavones on serum lipid levels in postmenopausal women, but the results were ambiguous. The objective of this study was to determine the relationship of dietary daidzein, genistein, and glycitein levels with lipid profile in postmenopausal women.<br /><br />Methods<br />A cross-sectional study was conducted involving 186 post-menopausal women. A food recall questionnaire was used to measure dietary genistein, daidzein, and glycitein levels. Serum total cholesterol (TC), low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triacylglycerol (TAG) were measured using the enzymatic colorimetric method. Simple and multivariate linear regression were used to analyze the data.<br /><br />Results<br />Genistein intake was significantly associated with TC (b=145.48, p=0.023) and HDL cholesterol levels (b=48.80, p=0.032). Daidzein intake was significantly associated with TC (b=-204.60, p=0.003), LDL cholesterol (b=-160.81, p=0.014) and HDL cholesterol levels (b=-67.118, p=0.032). Glycitein was not significantly associated with TC (b=232.78;p=0.133), HDL (b=43.59;p=0.428), and LDL (b=235.84;p=0.116). Dietary daidzein had a more lowering effect on TC (Beta=-2.80) and HDL cholesterol (Beta=-2.67) than had genistein on TC (Beta=2.66) and HDL cholesterol (Beta=2.03).<br /><br />Conclusions<br />High dietary daidzein level has a significant lowering effect on TC, LDL cholesterol and HDL cholesterol in post-menopausal women. Our study supports the advice given to the public to increase soy isoflavone intake in post-menopausal women.

scholarly journals Sonographic Abnormalities of Thyroid Gland in Post-Menopausal Women with and without Hormone Replacement Therapy

2021 ◽  
Vol 5 (2) ◽  
pp. 01-05
Author(s):  
Namra Adnan
Keyword(s):  
Hormone Replacement Therapy ◽  
Thyroid Gland ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Hormone Replacement ◽  
Mesh Terms ◽  
Menopausal Women ◽  
Study Results ◽  
Post Menopausal ◽  
Thyroid Abnormalities

Background: Thyroid dysfunction is common especially in women over the age of 50 years. The prevalence of thyroid abnormalities is more in postmenopausal women using hormone replacement therapy. The prevalence of biochemical (or subclinical) hypothyroidism in women increases steadily with age, rising from 10% to 20% in the postmenopausal. The study results clearly indicate an increase in the activities of TSH among the older-aged post-menopausal women. Objective: To compare the sonographic findings of thyroid gland in post-menopausal women with and without hormone replacement therapy. Material and Method: A review of scientific literature concerning the correlation of Sonographic abnormalities of thyroid gland in post-menopausal women with and without hormone replacement therapy was done. Different platforms including medical journals, books and online resources(e.g., PubMed, Google Scholar & Medline) were explored to find the relevant data using the mesh Terms: Thyroid gland, postmenopausal women, Hormone Replacement Therapy etc. The main focus was given to the latest data published in the last 10 years.

scholarly journals Effects of a Combination of Foeniculum vulgare, Melissa officinalis Extract, and Nigella saliva Powder on Healthy Menopausal Women with Sexual Dysfunction: A Randomized Clinical Trial

2020 ◽  
Vol 15 (3) ◽  
Author(s):  
Shima Afshar ◽  
Fariba Afshar ◽  
Amir Rezazade ◽  
Zeinab Shaker Ardakani ◽  
Zahra Jafari Azar ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Sexual Dysfunction ◽  
Sexual Function ◽  
Postmenopausal Women ◽  
Randomized Clinical Trial ◽  
Nigella Sativa ◽  
Melissa Officinalis ◽  
Foeniculum Vulgare ◽  
Menopausal Women ◽  
Nigella Sativa Seed

Background: Menopause is a critical period with frequent sexual disorders. Objectives: The current study assessed the therapeutic effect of a combination of the aerial part of Melissa officinalis, fennel fruit extract, and Nigella sativa seed powder on the sexual dysfunction of postmenopausal women. Methods: This randomized clinical trial was performed on 48 menopausal women from April 2015 to October 2017. The participants included the menopausal women referring to the clinic of Gorgan health centers aged between 41 and 54 years with natural menopause (amenorrhea for at least 12 months) and discomfort in sexual activity. They were randomized into two treatment groups. Group 1 (n = 27) received 1000 mg capsules (Melissa officinalis, fennel extract, and Nigella sativa powder), and group 2 (n = 21) received a placebo (1000 mg starch capsules (in an eight-week course of treatment (one capsule per day for each group). The variables in the female sexual function index (FSFI) questionnaire were compared in the two groups before and after the intervention. Results: The results showed that the mean scores of sexual dysfunction in the domains of arousal, lubrication, orgasm, satisfaction, and pain were not significantly different between the two groups (P > 0.05). Conclusions: Despite many studies on the effectiveness of Melissa, Foenculum, and Nigella, this study showed that a combination of Foeniculum vulgare, Melissa officinalis extract, and Nigella sativa seed powder does not improve the sexual function of postmenopausal women with sexual dysfunction, and it might be the synergism effect of this combination.

scholarly journals Peri- and Post-Menopausal Women with Schizophrenia and Related Disorders Are a Population with Specific Needs: A Narrative Review of Current Theories

2021 ◽  
Vol 11 (9) ◽  
pp. 849
Author(s):  
Alexandre González-Rodríguez ◽  
Armand Guàrdia ◽  
José Antonio Monreal
Keyword(s):  
Postmenopausal Women ◽  
Psychosocial Support ◽  
Controlled Trial ◽  
Hormone Replacement ◽  
Relevant Literature ◽  
Premenopausal Women ◽  
Narrative Review ◽  
Medical Comorbidities ◽  
Pubmed Database ◽  
Post Menopausal

Background: While gender differences in antipsychotic response have been recognized, the potential role of menopause in changing drug efficacy and clinical outcome in schizophrenia related disorders has been understudied. We aimed to review the relevant literature to test whether optimizing menopausal and post-menopausal treatment and addressing specific health needs of this stage in life will improve outcome. Methods: Non-systematic narrative review using the PubMed database (1900–July 2021) focusing on randomized controlled trial results addressing our question. Forty-nine studies met our criteria. Results: Premenopausal women show significantly better antipsychotic response than postmenopausal women. Hormone replacement therapies (HRT) should be used in postmenopausal women with schizophrenia with caution. Raloxifene, combined with antipsychotics, is effective for psychotic and cognitive symptoms in postmenopausal women with schizophrenia and related disorders. Medical comorbidities increase after menopause, but the influence of comorbidities on clinical outcomes has been poorly investigated. Preventive strategies include weighing risks and benefits of treatment, preventing medical comorbidities, and enhancing psychosocial support. Ideal treatment settings for this population warrant investigation. Conclusions: Antipsychotic dose adjustment at menopause is recommended for schizophrenia. Raloxifene may play an important role in permitting dose reduction and lessening adverse effects. Prevention of comorbidities will help to reduce the mortality rate.

Sign in / Sign up

Export Citation Format

Share Document